V. Heilmann

发表

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

A. Burges, F. Hilpert, A. Bois, 2005, Supportive Care in Cancer.

Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines

R. Kreienberg, I. Runnebaum, D. Kieback, 1994, Human Genetics.

Pretreatment Staging of Cervical Cancer: Is Imaging Better Than Palpation?

R. Kreienberg, C. Kurzeder, K. Hancke, 2008, Annals of Surgical Oncology.

Molecular biology of cervical cancer and its precursors.

R. Kreienberg, V. Heilmann, 2002, Current women's health reports.

Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion.

R. Kreienberg, H. Deissler, G. Sauer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

H. Döhner, L. Bergmann, J. Gschwend, 2002, Experimental hematology.

Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study

O. Sezer, K. Possinger, P. Schmid, 2005, Journal of Cancer Research and Clinical Oncology.

Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy

A. Rieber, A. Gabelmann, T. Kühn, 2002, European Radiology.

First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC).

M. Blettner, R. Kreienberg, M. Landthaler, 2010 .

Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany.

H. Tesch, A. Hinke, P. Dall, 2015, Journal of geriatric oncology.

Prognostic Impact of Satellite-Lymphovascular Space Involvement in Early-Stage Cervical Cancer

Jochem König, Daniel Herr, K. Koretz, 2008, Annals of Surgical Oncology.

Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.

S. Hauptmann, S. Kümmel, K. Possinger, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial

J. Blohmer, O. Sezer, K. Possinger, 2005, Anti-cancer drugs.

Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.

K. Ulm, J. Blohmer, S. Kümmel, 2006, Anticancer research.

Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

H. Hausmaninger, K. Possinger, P. Schmid, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of integrated papillomavirus sequences by ligation‐mediated PCR (DIPS‐PCR) and molecular characterization in cervical cancer cells

M. von Knebel Doeberitz, M. Nees, R. Klaes, 2001, International journal of cancer.

Abstract P6-11-05: NEPA for CINV prevention in highly or moderately emetogenic chemotherapy – interim results of a German non-interventional study on quality of life and efficacy

P. Klare, M. Karthaus, P. Wülfing, 2018 .

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

M. Beckmann, S. Loibl, T. Schuster, 2013, Breast Cancer Research and Treatment.

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

A. Hinke, Marcus Schmidt, C. Jackisch, 2010, BMC Cancer.

Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer.

R. Kreienberg, V. Heilmann, C. Jäger, 2004, Anticancer research.

Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study

J. Blohmer, K. Possinger, P. Schmid, 2004, Journal of Cancer Research and Clinical Oncology.

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.

A. Reuss, R. Kimmig, S. Loibl, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

376 Primary chemotherapy with gemcitabine (G), myocet (M) and docetaxel (T): results of a phase I/II trial

J. Blohmer, K. Possinger, P. Schmid, 2003 .

Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC

S. Loibl, J. Huober, C. Jackisch, 2005 .

NEUROPROTECTION WITH AMIFOSTINE IN THE 1ST-LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH CARBOPLATIN/TAXANE-BASED CHEMOTHERAPY – A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP

A. du Bois, A. Stahle, A. Burges, 2004, International Journal of Gynecologic Cancer.

Immunotherapy and cancer vaccines in the management of breast cancer.

R. Kreienberg, H. Deissler, G. Sauer, 2005, Current pharmaceutical design.

Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study

R. Kreienberg, O. Sezer, K. Possinger, 2005, Investigational New Drugs.